Autoimmune Autonomic Ganglionopathy (AAG)
Conditions
Keywords
Autoimmune autonomic neuropathy, Orthostatic hypotension, Dysautonomia, Autonomic failure, Peripheral autonomic neuropathy
Brief summary
The purpose of the study is to see if administering intravenous immune globulin (IVIG) (putting immune globulin directly into your blood) helps to improve the symptoms of orthostatic hypotension (sudden fall in blood pressure when a person stands up) and quality of life in men and women who have autoimmune autonomic ganglionopathy (AAG).
Detailed description
Autoimmune autonomic ganglionopathy (AAG) is a rare disease that results in severe dysautonomia (disorder of autonomic nervous system function). Many patients are unable to carry out activities of daily living due to autonomic symptoms that do not respond well to therapy (such as drops in blood pressure while standing). The recent discovery of antibodies that cause AAG has stimulated interest in immunomodulatory therapy (therapies that modify the functioning of the immune system). Studies in which a positive clinical response to these therapies have been reported in patients with AAG using immunomodulatory therapy as a treatment. The investigators plan to carry out a blinded, randomized trial using IVIG. There have been no reported randomized clinical trials with any immunosuppressive agent in AAG. The proposed studies, if successful, will provide the first reliable clinical evidence, that therapy with IVIG is an effective treatment of AAG. Treatment for the symptoms of autonomic failure is only effective in mild cases. Most patients require therapy that would change the course of the disease, but at present there is no established therapeutic regimen. The natural course of untreated AAG is not known. To address these unresolved issues, this clinical trial has the following goals: 1. To measure the effect of IVIG treatment on orthostatic hypotension, autonomic symptoms and quality of life scores in patient participants with AAG. 2. To determine the durability of IVIG (how long the treatment is effective) on orthostatic hypotension, autonomic symptoms and quality of life scores in patient participants with AAG. Participants enrolled in the study will receive two courses of intravenous immunoglobulin or placebo separated by 3 weeks. During the First Observation Period, participants will be evaluated after 6 weeks to determine the clinical response and natural history of the disorder. All the participants will then move to a single blinded second observation period. All patients enrolled in the study (IVIG group and placebo group) will receive two infusions of intravenous immunoglobulin, i.e., both cohorts will receive IVIG (although participants will not know this, and physicians will not be aware if this treatment is to IVIG naïve or IVIG continued participants).
Interventions
DRUGDouble blinded IVIg
Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
OTHERDouble blinded Placebo
Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
OTHERSingle Blinded IVIg
This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
Sponsors
Mayo Clinic
Vanderbilt University
NYU Langone Health
University of Texas Southwestern Medical Center
National Institute of Neurological Disorders and Stroke (NINDS)
Beth Israel Deaconess Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
To prevent unblinding because of observed efficacy, adverse events or changes in laboratory values, each site will have both a treating investigator and an examining investigator. The treating investigator will assess the participant's clinical response and laboratory findings. The treating investigator will make all clinical treatment decisions. The examining investigator will monitor only the clinical autonomic symptoms and quality of life scores, and autonomic tests. Both the treating and examining investigators should be physicians. To prevent infusion unblinding, infusions of IVIG and placebo will occur in opaque bags.
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Participants aged 18 to 85 2. Participants have neurogenic orthostatic hypotension (fall in systolic blood pressure \> 30 mmHg). 3. Symptoms of orthostatic intolerance. 4. Antibodies to the neuronal AChR of the autonomic ganglia of \>0.2nmol/l. Results must be within 6 months of the screening visit and there may not have been any immunomodulatory interventions since the time of the antibody measurement or the sample will need to be reconfirmed at screening. 5. Participants must be willing to withdraw from medications that affect vasoactive and autonomic function for 5 half-lives during testing (with the exception of stable doses of fludrocortisone up to 0.2 mg/day) and adhere to a regular diet
Exclusion criteria
1. Women of childbearing potential (WOCP) who are not using a medically accepted contraception 2. Pregnant or lactating females- if participants become pregnant during the trial they will no longer receive IVIG, but will be followed as part of the intention to treat protocol. 3. Severe depression and/or anxiety (score of \> 29 on the Beck Depression Inventory or score on the Beck Anxiety Inventory of ≥ 36) 4. Active psychosis is ineligible, history of psychosis will be eligible, but only after review with the patients PCP and/or treating mental health provider. 5. History of asthma 6. Other causes of autonomic failure (e.g., diabetes, amyloidosis) 7. History of allergic or anaphylactic reaction to humanized or murine antibodies. 8. History or presence of recurrent or chronic infection (recurrent infections defined as \>4 times per year). 9. History of cancer, including solid tumors and hematologic malignancies (except fully resolved and resected cutaneous basal cell and squamous cell carcinomas of the skin) 10. History or presence of vascular disease potentially affecting brain or spinal cord (e.g., stroke, transient ischemic attack, carotid stenosis (greater than 80%), aortic aneurysm, intracranial aneurysm, hemorrhage, arteriovenous malformation) 11. History of severe, clinically significant central nervous system trauma (e.g., cerebral contusion, spinal cord compression) 12. History or presence of infectious causes of encephalopathy or myelopathy (e.g., syphilis, Lyme disease, human T-cell lymphotropic virus type 1 \[HTLV-1\], herpes zoster myelopathy) 13. History of thromboembolic events or deep vein thrombosis 14. Platelet count \<100,000/mL, Hemoglobin \<8.5 g/dL, Neutrophils \<1.5 x 103/mL. 15. Serum IgA deficiency: Immunoglobulin A (IgA) level \< 7 mg/dL. 16. History of immunosuppression or HIV/AIDS 17. History of cardiac arrhythmia or angina, electrocardiogram (ECG) showing significant abnormality that the treating investigator determines may jeopardize the participant's health (i.e., acute ischemia, left bundle branch, or bifascicular block) 18. History of renal failure or creatinine \>2.0 19. History of previous allergic response to albumin. 20. Treatment with IVIG or plasma exchange within 6 weeks of study enrollment. 21. Active adjustments of other immunomodulatory treatments. Patients that are on stable doses of immunomodulatory medications (no dose changes within 4 months -including, but not limited to prednisone, mycophenolate mofetil or azathioprine) but still have elevated antibody titers and meet criteria for inclusion will be allowed to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) | Baseline and 6 weeks | The primary outcome, the change in systolic blood pressure during 60 degree tilt (ΔSBP), will be assessed in all study participants at baseline and at 6 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) | 6 weeks and 12 weeks | To compare the change in systolic blood pressure during 60 degree head up tilt table test after 6 and 12 weeks of IVIG (the within-patient difference in ΔSBP at 12 and 6 weeks among treated patients). |
| Composite Autonomic Symptom Score [COMPASS] Questionnaire | Baseline, 6 weeks | To determine the change in autonomic symptoms (measured by the composite autonomic symptom score \[COMPASS\] questionnaire) measured at baseline and 6 weeks. Minimum and maximum score possible: 0-100. We have reported the Total score. Higher values represent worse outcome. |
| Composite Autonomic Severity Score (CASS) Questionnaire. | Baseline, 6 weeks | To determine the change in autonomic symptoms (measured by the composite autonomic severity score \[CASS\]) measured at baseline and 6 weeks in individuals receiving IVIg. Is a 10-point composite autonomic scoring scale of autonomic function. This scale allots 4 points for adrenergic and 3 points each for sudomotor and cardiovagal failure. Subjects with a score of 3 or less on have a mild autonomic failure, 4-6 have moderate autonomic failure and those with scores of 7 to 10 have severe failure. The minimum score possible is 3 and maximum is 10. |
| EuroQol [EQ-5D] Questionnaire. | Baseline, 6 weeks | To determine the change in quality of life (measured by the EuroQol \[EQ-5D\]) measured at baseline and 6 weeks in individuals receiving IVIg. We have reported the subscale (EQ-VAS). The minimum score is 0 and maximum score is 100. (0) corresponds to the worst health you can imagine, and the highest rate (100) corresponds to the best health you can imagine. |
| Orthostatic Hypotension Symptom Assessment Questionnaire | Baseline, 6 weeks | To determine the change in orthostatic Hypotension symptom (measured by the orthostatic hypotension symptom assessment questionnaire) measured at baseline and 6 weeks in individuals receiving IVIG. This is a 60 point orthostatic hypotenstion symptom assessment questionnaire. The minimum score possible is 0 and maximum is 60. Higher values represent worse outcome. We are reporting the total score. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Group A IVIg
IVIG: Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
They will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. | 3 |
| Group B Placebo
2 treatments of placebo and 2 treatments of IVIg: Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
They will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. | 3 |
| Total | 6 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Physician Decision | 1 | 1 |
Baseline characteristics
| Characteristic | Group A | Group B | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 3 Participants | 6 Participants |
| Sex: Female, Male Female | 1 Participants | 3 Participants | 4 Participants |
| Sex: Female, Male Male | 2 Participants | 0 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 |
| other Total, other adverse events | 1 / 2 | 3 / 3 |
| serious Total, serious adverse events | 0 / 3 | 0 / 3 |
Outcome results
Primary
Change in Systolic Blood Pressure During 60° Tilt (ΔSBP)
The primary outcome, the change in systolic blood pressure during 60 degree tilt (ΔSBP), will be assessed in all study participants at baseline and at 6 weeks.
Time frame: Baseline and 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IVIg Group | Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) | 42.5 mmHg | Standard Deviation 54.4 |
| Placebo Group | Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) | -12.3 mmHg | Standard Deviation 38 |
Secondary
Change in Systolic Blood Pressure During 60° Tilt (ΔSBP)
To compare the change in systolic blood pressure during 60 degree head up tilt table test after 6 and 12 weeks of IVIG (the within-patient difference in ΔSBP at 12 and 6 weeks among treated patients).
Time frame: 6 weeks and 12 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IVIg Group | Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) | -26 mmHg | Standard Deviation 43.8 |
| Placebo Group | Change in Systolic Blood Pressure During 60° Tilt (ΔSBP) | -7.6 mmHg | Standard Deviation 7.09 |
Secondary
Composite Autonomic Severity Score (CASS) Questionnaire.
To determine the change in autonomic symptoms (measured by the composite autonomic severity score \[CASS\]) measured at baseline and 6 weeks in individuals receiving IVIg. Is a 10-point composite autonomic scoring scale of autonomic function. This scale allots 4 points for adrenergic and 3 points each for sudomotor and cardiovagal failure. Subjects with a score of 3 or less on have a mild autonomic failure, 4-6 have moderate autonomic failure and those with scores of 7 to 10 have severe failure. The minimum score possible is 3 and maximum is 10.
Time frame: Baseline, 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IVIg Group | Composite Autonomic Severity Score (CASS) Questionnaire. | 0.5 units | Standard Deviation 0.7 |
| Placebo Group | Composite Autonomic Severity Score (CASS) Questionnaire. | 0 units | Standard Deviation 0 |
Secondary
Composite Autonomic Symptom Score [COMPASS] Questionnaire
To determine the change in autonomic symptoms (measured by the composite autonomic symptom score \[COMPASS\] questionnaire) measured at baseline and 6 weeks. Minimum and maximum score possible: 0-100. We have reported the Total score. Higher values represent worse outcome.
Time frame: Baseline, 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IVIg Group | Composite Autonomic Symptom Score [COMPASS] Questionnaire | -5 units | Standard Deviation 2.8 |
| Placebo Group | Composite Autonomic Symptom Score [COMPASS] Questionnaire | -0.33 units | Standard Deviation 5.13 |
Secondary
EuroQol [EQ-5D] Questionnaire.
To determine the change in quality of life (measured by the EuroQol \[EQ-5D\]) measured at baseline and 6 weeks in individuals receiving IVIg. We have reported the subscale (EQ-VAS). The minimum score is 0 and maximum score is 100. (0) corresponds to the worst health you can imagine, and the highest rate (100) corresponds to the best health you can imagine.
Time frame: Baseline, 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IVIg Group | EuroQol [EQ-5D] Questionnaire. | 15 units | Standard Deviation 21.2 |
| Placebo Group | EuroQol [EQ-5D] Questionnaire. | 9.3 units | Standard Deviation 22.8 |
Secondary
Orthostatic Hypotension Symptom Assessment Questionnaire
To determine the change in orthostatic Hypotension symptom (measured by the orthostatic hypotension symptom assessment questionnaire) measured at baseline and 6 weeks in individuals receiving IVIG. This is a 60 point orthostatic hypotenstion symptom assessment questionnaire. The minimum score possible is 0 and maximum is 60. Higher values represent worse outcome. We are reporting the total score.
Time frame: Baseline, 6 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IVIg Group | Orthostatic Hypotension Symptom Assessment Questionnaire | -9 units | Standard Deviation 2.8 |
| Placebo Group | Orthostatic Hypotension Symptom Assessment Questionnaire | 12 units | Standard Deviation 9.5 |